ESC 2026: Pacibekitug (IL-6 ligand mAb) in patients with CKD and high CV risk

📚 ESC 2026 coverage: Can a response-tailored shorter antibiotic strategy be a safe alternative to standard therapy in infective endocarditis? by Dr. Hafezi, general cardiologist....

📚 ESC 2026 coverage: How can a digital registry system improve the implementation of SGLT2 inhibitors in heart failure patients? by Dr. Taghavi, fellowship of heart failure....

📚 ESC 2026 coverage: Is Factor XIa inhibition the future of antithrombotic therapy after ACS?by Dr. Aghakouchakzadeh, Clinical Pharmacist....

📚 ESC 2026 coverage: Will Plozasiran become a new therapeutic option for patients with severe hypertriglyceridaemia?by Dr. Ghanouni, Endocrinologist....

📚 ESC 2026 coverage: Does a team-based collaborative care model improve outcomes in patients with heart failure?by Dr. Ranjbar, fellowship of heart failure....

📚 ESC 2026 coverage: Does eplontersen demonstrate efficacy and safety in patients with transthyretin amyloid cardiomyopathy?by Dr. Kakavand, Clinical Pharmacist....

📚 ESC 2026 coverage: Does anticoagulation reduce stroke risk in patients with atrial fibrillation at intermediate risk? by Dr. Oraii, fellowship of electrophysiology....

📚 ESC 2026 coverage: Do statins reduce cardiovascular events and disability in older adults? by Dr. Chehrehgosha, endocrinologist....

📚 ESC 2026 coverage: Does aficamten improve symptoms in patients with symptomatic non-obstructive hypertrophic cardiomyopathy? by Dr. Mirtajaddini, fellowship of heart failure....